ID   Ma-Mel-11
AC   CVCL_A133
SY   MaMel-11; MaMel11
DR   BTO; BTO_0005339
DR   cancercelllines; CVCL_A133
DR   Cosmic; 1467740
DR   Cosmic; 1846578
DR   Cosmic; 2163820
DR   Cosmic; 2686350
DR   ESTDAB; ESTDAB-108
DR   GEO; GSM436991
DR   Progenetix; CVCL_A133
DR   Wikidata; Q54903744
RX   PubMed=19340423;
RX   PubMed=20544847;
RX   PubMed=23348503;
RX   PubMed=23851445;
RX   PubMed=26909863;
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=26909863).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=23348503; PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Phe90_Pro95delinsLeu (c.270_284del); Zygosity=Unspecified (PubMed=23851445).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=23348503).
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
ST   Source(s): ESTDAB=ESTDAB-108
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 12
ST   D3S1358: 17
ST   D5S818: 10,11
ST   D7S820: 10
ST   FGA: 25,26
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 14,16
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 10-04-25; Version: 23
//
RX   PubMed=19340423; DOI=10.1007/s00262-009-0701-z; PMCID=PMC11030131;
RA   Mendez R., Aptsiauri N., Del Campo A., Maleno I., Cabrera T.,
RA   Ruiz-Cabello Osuna F., Garrido F., Garcia-Lora A.;
RT   "HLA and melanoma: multiple alterations in HLA class I and II
RT   expression in human melanoma cell lines from ESTDAB cell bank.";
RL   Cancer Immunol. Immunother. 58:1507-1515(2009).
//
RX   PubMed=20544847; DOI=10.1002/gcc.20785;
RA   Gast A., Scherer D., Chen B.-W., Bloethner S., Melchert S., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Somatic alterations in the melanoma genome: a high-resolution
RT   array-based comparative genomic hybridization study.";
RL   Genes Chromosomes Cancer 49:733-745(2010).
//
RX   PubMed=23348503; DOI=10.1126/science.1230062;
RA   Horn S., Figl A., Rachakonda P.S., Fischer C., Sucker A., Gast A.,
RA   Kadel S., Moll I., Nagore E., Hemminki K., Schadendorf D., Kumar R.;
RT   "TERT promoter mutations in familial and sporadic melanoma.";
RL   Science 339:959-961(2013).
//
RX   PubMed=23851445; DOI=10.1158/1541-7786.MCR-13-0006;
RA   Dahl C., Christensen C., Jonsson G., Lorentzen A., Skjodt M.L.,
RA   Borg A., Pawelec G., Guldberg P.;
RT   "Mutual exclusivity analysis of genetic and epigenetic drivers in
RT   melanoma identifies a link between p14 ARF and RARbeta signaling.";
RL   Mol. Cancer Res. 11:1166-1178(2013).
//
RX   PubMed=26909863; DOI=10.18632/oncotarget.7503; PMCID=PMC4941330;
RA   Xie H.-P., Rachakonda P.S., Heidenreich B., Nagore E., Sucker A.,
RA   Hemminki K., Schadendorf D., Kumar R.;
RT   "Mapping of deletion breakpoints at the CDKN2A locus in melanoma:
RT   detection of MTAP-ANRIL fusion transcripts.";
RL   Oncotarget 7:16490-16504(2016).
//